Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

mRNA 5671

Next Previous
Drug Profile

mRNA 5671

Alternative Names: KRAS vaccine - Moderna Therapeutics; mRNA-5671; Mutant KRAS vaccine - Moderna Therapeutics; V 941

Latest Information Update: 06 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Moderna Therapeutics
  • Developer Merck & Co; Moderna Therapeutics
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 28 Jan 2025 Merck Sharp & Dohme terminates a phase I trial in Non-small cell lung cancer, Colorectal cancer, Pancreatic cancer (Metastatic disease, Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater) in USA, Australia, Hong Kong, South Korea, New Zealand, Singapore and Taiwan (IM), due to business reasons (NCT03948763)
  • 12 Sep 2024 Discontinued - Phase-I for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia, Hong Kong, South Korea, New Zealand, Singapore, Taiwan (IM)
  • 12 Sep 2024 Discontinued - Phase-I for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in New Zealand, Taiwan, Australia, Hong Kong, South Korea, Singapore (IM)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top